ER
AGRX

Enlightenment Research’s Agile Therapeutics AGRX Stock Holding History

Enlightenment Research’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5
Closed -$28K – 211
2020
Q1 		$28K Buy
+5
New +$28.7K 0.03% 164

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Enlightenment Research's AGRX Position: Q2 2020 in Review

Enlightenment Research sold out of Agile Therapeutics (AGRX) in Q2 2020, closing a stake of 5 shares — an estimated $28K sold.

Enlightenment Research first reported a position in AGRX in Q1 2020 and held it in 1 quarter. The position peaked at $28K in Q1 2020. 79 funds tracked by Wall St. Rank hold AGRX as of Q2 2020.

  • Enlightenment Research reported no remaining Agile Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Enlightenment Research sold 5 Agile Therapeutics shares in Q2 2020, an estimated $28K.
  • Enlightenment Research first reported a position in Agile Therapeutics in Q1 2020 and held it in 1 quarter.
  • Enlightenment Research's Agile Therapeutics position peaked at $28K in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2020.

Based on Enlightenment Research's 13F filing for Q2 2020, filed 6 Aug 2020.